# Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19

> **NCT04732949** · PHASE3 · COMPLETED · sponsor: **Synairgen Research Ltd.** · enrollment: 623 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2
- COVID-19

## Interventions

- **DRUG:** SNG001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04732949
- **Lead sponsor:** Synairgen Research Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-12
- **Primary completion:** 2021-12-15
- **Final completion:** 2022-02-10
- **Target enrollment:** 623 (ACTUAL)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04732949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04732949, "Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04732949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*